Hikma Pharmaceuticals USA Inc. secured FDA approval for its generic nasal butorphanol tartrate product, reinforcing its strategic expansion within the pain management sector. This approval is expected to enhance generic availability and apply competitive pricing pressure to branded analgesic alternatives.